Huakang Biomedical Holdings
Huakang Biomedical Holdings, a prominent player in the biotechnology sector, is headquartered in Hong Kong (HK) and operates extensively across Asia. Founded in 2001, the company has established itself as a leader in the development and manufacturing of innovative medical devices and diagnostic solutions, particularly in the fields of molecular diagnostics and point-of-care testing. With a commitment to enhancing healthcare outcomes, Huakang Biomedical offers a range of unique products, including advanced diagnostic kits that leverage cutting-edge technology. The company’s focus on research and development has led to significant milestones, positioning it as a trusted name in the industry. Recognised for its quality and reliability, Huakang Biomedical continues to expand its market presence, contributing to the advancement of healthcare solutions in the region.
DitchCarbon Score
How does Huakang Biomedical Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Huakang Biomedical Holdings's score of 21 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Huakang Biomedical Holdings's reported carbon emissions
In 2022, Huakang Biomedical Holdings reported total carbon emissions of approximately 124,200 kg CO2e. This figure includes 15,660 kg CO2e from Scope 1 emissions, primarily from mobile combustion, and 103,520 kg CO2e from Scope 2 emissions related to purchased electricity. Additionally, Scope 3 emissions accounted for about 5,020 kg CO2e, with significant contributions from business travel and waste generated in operations. Over the years, the company has shown fluctuations in its emissions. For instance, in 2021, total emissions were approximately 121,140 kg CO2e, while in 2020, they were about 145,050 kg CO2e. This indicates a general trend of emissions reduction from 2020 to 2022, despite a slight increase in Scope 1 emissions in 2022 compared to 2021. Huakang Biomedical Holdings has not publicly committed to specific reduction targets or initiatives, nor have they aligned with the Science Based Targets initiative (SBTi). However, the company continues to monitor and report its emissions across all three scopes, demonstrating a commitment to transparency in its climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | 15,000 | 0,000 | 00,000.0 | 00,000 | 00,000 |
| Scope 2 | 155,000 | 000,000 | 00,000.0 | 000,000 | 000,000 |
| Scope 3 | 4,000 | 0,000 | 00,000 | 0,000 | 0,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Huakang Biomedical Holdings is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
